Adagene Inc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-26.9%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.52next fiscal year
Monitoring Framework
Key Performance Indicators
Muzastotug (ADG126) Phase 1b/2 MSS CRC Confirmed Overall Response Rate (ORR) Annually2,900.0%Target: Demonstrate superior efficacy over standard of care (fruquintinib/regorafenib) in randomized Phase 2
Cash and Cash Equivalents (USD Millions) Quarterly74.5Target: Maintain sufficient runway into early 2028
Muzastotug (ADG126) Phase 1b/2 MSS CRC Median Overall Survival (mOS) in 10 mg/kg cohorts (Months) Annually19.4Target: Exceed historical 11-12 months mOS of standard of care
Watch Items
- Muzastotug (ADG126) Randomized Phase 2 Dose-Optimization Study ProgressTrigger: First patient dosed in October 2025; interim data updates expected in late 2026/2027Action: Monitor clinical trial registries and corporate updates for patient enrollment rates and safety/efficacy readouts.
- Sanofi and Roche Strategic CollaborationsTrigger: Sanofi strategic investment of up to $25 million and Roche-sponsored Phase 1b/2 triple combination trial in HCCAction: Track milestone achievements, option exercises, and clinical data releases from partner-sponsored trials.
Research as of 19 Jun 2026